This is a working overview of prohibited list, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-26. Anything still debated is marked as such rather than presented as settled.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
=== Aspartame === In 2008, Ajinomoto sued British supermarket chain Asda, part of Walmart, for a malicious falsehood action concerning its aspartame product when the chemical was listed as excluded from the chain's product line along with other "nasties". In July 2009, a British court found the case in Asda's favor. In June 2010, an appeal court reversed the decision, allowing Ajinomoto to pursue a case against Asda to protect the reputation of its aspartame. At that time, Asda said that it would continue to use the term "no nasties" on its own-label products, but the suit was settled out of court in 2011 after Asda removed references to aspartame from its packaging.
=== "Revolution within a Revolution": 1987–1998 === The late 1980s saw a series of liberalizing economic reforms within Libya designed to cope with the decline in oil revenues. In May 1987, Gaddafi announced the start of the "Revolution within a Revolution", which began with reforms to industry and agriculture and saw the re-opening of small business. Restrictions were placed on the activities of the Revolutionary Committees; in March 1988, their role was narrowed by the newly created Ministry for Mass Mobilization and Revolutionary Leadership to restrict their violence and judicial role, while in August 1988 Gaddafi publicly criticized them. In March, hundreds of political prisoners were freed, with Gaddafi falsely claiming that there were no further political prisoners in Libya. In June, Libya's government issued the Great Green Charter on Human Rights in the Era of the Masses, in which 27 articles laid out goals, rights, and guarantees to improve the situation of human rights in Libya, restricting the use of the death penalty and calling for its eventual abolition. Many of the measures suggested in the charter would be implemented the next year, although others remained inactive. Also in 1989, the government founded the Al-Gaddafi International Prize for Human Rights, to be awarded to figures from the Third World who had struggled against colonialism and imperialism; the first year's winner was South African anti-apartheid activist Nelson Mandela.
== External links == Interview with Roderick MacKinnon by Harry Kroto Freeview video provided by the Vega Science Trust. Website of his lab at The Rockefeller University Ion Channel Chemistry: The Electrical System of Life Transcribed video of a May 2008 talk by MacKinnon, sponsored by the Oregon State University Libraries. Nobel Lecture by Roderick MacKinnon, 2003 Introduction to Neuroscience by Donald C.Cooper Roderick MacKinnon on Nobelprize.org
==== Endogenous DMT ==== N,N-Dimethyltryptamine (DMT), a psychedelic compound identified endogenously in mammals, is biosynthesized by aromatic L-amino acid decarboxylase (AADC) and indolethylamine-N-methyltransferase (INMT). Studies have investigated brain expression of INMT transcript in rats and humans, coexpression of INMT and AADC mRNA in rat brain and periphery, and brain concentrations of DMT in rats. INMT transcripts were identified in the cerebral cortex, pineal gland, and choroid plexus of both rats and humans via in situ hybridization. Notably, INMT mRNA was colocalized with AADC transcript in rat brain tissues, in contrast to rat peripheral tissues where there existed little overlapping expression of INMT with AADC transcripts. Additionally, extracellular concentrations of DMT in the cerebral cortex of normal behaving rats, with or without the pineal gland, were similar to those of canonical monoamine neurotransmitters including serotonin. A significant increase of DMT levels in the rat visual cortex was observed following induction of experimental cardiac arrest, a finding independent of an intact pineal gland. These results show for the first time that the rat brain is capable of synthesizing and releasing DMT at concentrations comparable to known monoamine neurotransmitters and raise the possibility that this phenomenon may occur similarly in human brains. The first claimed detection of endogenous DMT in mammals was published in June 1965: German researchers F. Franzen and H.
Narrated by Robin Ellis, produced by Rachel Allen, directed by Sarah Marris, made by TVF Media 24 May Storm in a D Cup, about breast implants; Sally Kirkland was a main protagonist against implants; Sybil Niden Goldrich of the Command Trust Network; Marcia Angell of The New England Journal of Medicine; the British 1990s glamour model Teresa May; Roger Sturrock of the University of Glasgow; Dennis Deapen of the University of Southern California; Sai Ramastry of the University of Illinois Chicago; British 1990s glamour model Hannah Callow sat nonchalantly on a London underground train, with surreptitious nearby male attention. Directed by Martin Durkin (often chose quite controversial topics), made by his company Kugelblitz 7 June Curse of the Phantom Limbs, about sensations of phantom limbs; Jackie Naylor lost her hand in an accident on the A57 in 1989; neuroscientist Peter Halligan, since 2018 the Chief Scientific Adviser for Wales; photographer Alexa Wright makes superfiction images of phantom limbs; the Douglas Bader Centre at the Queen Mary's Hospital, Roehampton; Canadian psychologist Ronald Melzack of McGill University; Conrad Weiskrantz, son of neuroscientist Lawrence Weiskrantz had a motorbike accident on a country road, where he hit a vehicle towing a trailer turning right; the Silver Spring monkeys; neuroscientist V. S. Ramachandran of University of California, San Diego; Canadian neurosurgeon Wilder Penfield conducted cortical stimulation mapping research in the 1950s, resulting in the cortical homunculus and cortical maps; neurosurgeon Tipu Aziz.
Sources: en.wikipedia.org
=== Studies in vitro === Epitalon appears to induce telomere elongation via increased telomerase activity in human somatic cells in vitro, based on a study in human fibroblast cell cultures. Elongation of telomeres by epitalon was sufficient to surpass the Hayflick limit in a cell culture of human fetal fibroblast cells, extending their proliferative potential from termination at the 34th passage in the control cell population to beyond the 44th passage in the treated cell population, while increasing the lengths of their telomeres to levels comparable to those of cells in the original culture. Epitalon induces decondensation of heterochromatin near the centromeres in cultured lymphocytes originating from samples taken from humans of ages 76 to 80 years. Epitalon appears to inhibit the synthesis of the MMP9 protein in vitro in aging skin fibroblasts.
Caution, however, is generally prudent when doing this, as seizures, which are more likely to occur with clomipramine than every other tricyclic antidepressant besides maprotiline, become more and more of a risk beyond the normally-recommended upper-ceiling. At daily doses ≤ 250 mg, the incidence of seizures may be reliably estimated to be around the order of 0.48%. (All tricyclic antidepressants technically lower the seizure-threshold but this is only significant with amoxapine, maprotiline and, indeed, clomipramine.) Dose-increases between 25 mg and 150 mg, barring significant drug-drug interactions which may elevate clomipramine blood-levels, should be titrated in doses of 50 mg (25 mg in the case of panic disorder and 10 to 25 mg in the cases of premature ejaculation and narcoleptic cataplexy) and above 150 mg in 25 mg increments. Average optimal total daily doses for depression (whether mild or severe), premature ejaculation, cataplexy-narcolepsy, obsessive–compulsive disorder, panic disorder and trichotilomania respectively are (in milligrams) 150, 50, 25 - 75, 150 - 250, 50 - 150 and 150 - 200. Some consider the minimum optimally-therapeutic dose of clomipramine in obsessive-compulsive disorder, which often requires much higher levels of serotonergic concentration than other indications for these drugs, to be 200, rather than 150, milligrams per day. For premature ejaculation, clomipramine can be taken prn 3 to 5 hours before attempted sexual intercourse.
== Mechanism of action == Avalglucosidase alfa is composed of the human GAA enzyme that is conjugated with a couple of bis-mannose-6-phosphate (bis-M6P) tetra-mannose glycans. The bis-MGP of avalglucosidase alpha binds to the cation-independent mannose-6-phosphate receptor which is located on the skeletal muscles. Once the molecule binds to the receptor, the drug enters the cell. The drug then enters the lysosomes of the cell. Within the lysosome of the cell, the drugs undergoes cleavage proteolytically and then acts as an enzyme.
Hegseth defended the domestic military deployments by the second Trump administration. In September 2025, Hegseth gathered the Department of Defense's senior military leaders to Quantico, Virginia, for an address calling for tighter fitness standards and opposition to "woke garbage". The event featured Trump. On November 24, 2025, Hegseth ordered a review of "serious allegations of misconduct" against Senator Mark Kelly — a retired Navy officer who had posted a video urging military and intelligence officials not to obey any illegal orders from the Trump Administration — with the explicit mention of potential "recall to active duty for court-martial procedures or administrative measures". Secretary of the Navy John Phelan was then tasked with this review and ordered to complete it by December 10, 2025. On January 5, 2026, Hegseth issued a Secretarial Letter of Censure against Senator Kelly in his capacity as a retired Navy Captain, without the right to appeal. On the same day, Senator Kelly was notified by the Office of the Chief of Naval Personnel that Retirement Grade Determination Proceedings would be started based on Hegseth's aforementioned Letter of Censure. In February 2026, a grand jury declined to return an indictment against Kelly and the others for the video. A federal judge subsequently issued a temporary injunction against Hegseth's proposed actions on Kelly's rank and pension based on the significant merits and very high likelihood of success of Kelly's appeal to protection of free speech under the First Amendment.
Sources: en.wikipedia.org
=== Molecular paint or carpet peptides === This class of peptides undergoes self-assembling on a surface and form monolayers just few nanometers thick. These types of molecular "paint" or "carpet" peptides are able to form cell patterns, interacting with or trapping other molecules onto the surface. This class of peptides consists of three segments: the head is a ligand part, which has functional groups attached for recognition by other molecules or cell surface receptors; the middle segment is a "linker", allows the head to interact at a distance away from the surface and which also controls the flexibility and the rigidity of the peptide structure; and, at the other end of the linker, a surface anchor where a chemical group on the peptide forms a covalent bond with a particular surface. This class of peptides has the unique property of being able to change molecular structure dramatically. This property is best illustrated using an example. The DAR16-IV peptide, has 16 amino acids and forms a 5 nm β-sheet structure at ambient temperatures; a swift change in structure occurs at high temperature or a change in pH when a 2.5 nm α-helix forms.
=== Monoamine oxidase inhibitors === Monoamine oxidase inhibitors (MAOIs) are first-generation antidepressants effective for anxiety treatment but their dietary restrictions, adverse effect profile and availability of newer medications have limited their use. MAOIs include phenelzine, isocarboxazid and tranylcypromine. Pirlindole is a reversible MAOI that lacks dietary restriction.
=== Indonesia === Indonesia, although an oil producer itself, imports around a third of its supply. As the largest economy in Southeast Asia, it keeps a fuel reserve of around 22 days. The shortage in fuel imports have caused prices for unsubsidized fuel to increase by up to 32%, as well as a surge in spending for fuel, electricity, and fertilizers subsidies to double that of last year.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.